Cargando…

Recent Developments in the Treatment of Childhood Atopic Eczema

Even with the most careful application of conventional treatment, atopic eczema can be a disabling handicap in severely affected children. In refractory cases the conventional therapeutic options— potent topical steroids or the use of systemic steroids—are potentially hazardous and associated with r...

Descripción completa

Detalles Bibliográficos
Autor principal: David, T. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal College of Physicians of London 1991
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377204/
https://www.ncbi.nlm.nih.gov/pubmed/2066937
_version_ 1782519267706535936
author David, T. J.
author_facet David, T. J.
author_sort David, T. J.
collection PubMed
description Even with the most careful application of conventional treatment, atopic eczema can be a disabling handicap in severely affected children. In refractory cases the conventional therapeutic options— potent topical steroids or the use of systemic steroids—are potentially hazardous and associated with relapse after therapy has been discontinued. The main drawbacks to recent experimental approaches, such as oral cyclosporin, photochemotherapy or interferon-γ, are relapse after cessation of therapy and potentially serious side-effects. Avoidance of certain foods, pets and house dust mites is an option, the major drawbacks being the lack of tests to identify triggers or predict response, and the possible nutritional or psychological hazards of elimination diets. Difficulties with these approaches emphasise the need for close attention to the details of conventional treatment.
format Online
Article
Text
id pubmed-5377204
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Royal College of Physicians of London
record_format MEDLINE/PubMed
spelling pubmed-53772042019-01-22 Recent Developments in the Treatment of Childhood Atopic Eczema David, T. J. J R Coll Physicians Lond Overview Even with the most careful application of conventional treatment, atopic eczema can be a disabling handicap in severely affected children. In refractory cases the conventional therapeutic options— potent topical steroids or the use of systemic steroids—are potentially hazardous and associated with relapse after therapy has been discontinued. The main drawbacks to recent experimental approaches, such as oral cyclosporin, photochemotherapy or interferon-γ, are relapse after cessation of therapy and potentially serious side-effects. Avoidance of certain foods, pets and house dust mites is an option, the major drawbacks being the lack of tests to identify triggers or predict response, and the possible nutritional or psychological hazards of elimination diets. Difficulties with these approaches emphasise the need for close attention to the details of conventional treatment. Royal College of Physicians of London 1991-04 /pmc/articles/PMC5377204/ /pubmed/2066937 Text en © Journal of the Royal College of Physicians of London 1991 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits non-commercial use and redistribution provided that the original author and source are credited.
spellingShingle Overview
David, T. J.
Recent Developments in the Treatment of Childhood Atopic Eczema
title Recent Developments in the Treatment of Childhood Atopic Eczema
title_full Recent Developments in the Treatment of Childhood Atopic Eczema
title_fullStr Recent Developments in the Treatment of Childhood Atopic Eczema
title_full_unstemmed Recent Developments in the Treatment of Childhood Atopic Eczema
title_short Recent Developments in the Treatment of Childhood Atopic Eczema
title_sort recent developments in the treatment of childhood atopic eczema
topic Overview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377204/
https://www.ncbi.nlm.nih.gov/pubmed/2066937
work_keys_str_mv AT davidtj recentdevelopmentsinthetreatmentofchildhoodatopiceczema